Route of injection doesn't change the code
The Pharmacy Compounding Advisory Committee is scheduled to review BPC-157 on July 23, 2026 for possible inclusion on the 503A bulks list
Gastroprotection & Cytoprotection : Consistent with its origin, BPC-157 has repeatedly reduced gastric and intestinal lesion severity in preclinical models and supported mucosal closure.[3] Nitric-Oxide System Balancing : BPC-157 has normalised haemodynamics in settings of both nitric-oxide deficiency and excess, pointing to a homeostatic effect on vascular tone and tissue perfusion
Rather than directly supplying NAD+ precursors (like NMN or NR), it works by blocking an enzyme that consumes nicotinamide, theoretically preserving the substrate pool for endogenous NAD+ production
Be aware of any specific regulations regarding the use and distribution of BPC-157 in your jurisdiction
Seiwerth, S., Milavic, M., Vukojevic, J., Gojkovic, S., Krezic, I., Vuletic, L